-
Djokovic wins Basel opener to boost ATP Finals bid
-
تركيزات قياسية لغازات الاحتباس الحراري في الغلاف الجوي خلال 2025
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Cuba wins UN vote against US embargo with weakest backing in 30 years
-
Chiefs sign ex-Ravens kicker suspended over sex allegations
-
شباب من أجل الاستدامة تفتح التسجيل لبرامج 2027 في عامها العاشر
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
Inglis and Carey put Australia in command of South Africa decider
-
From Gaza to Ramallah, Palestinians see little hope in Israeli vote
-
92-year-old US judge handling Maduro case dies
-
US labor leader Dolores Huerta dead: family
-
Perez extends Cadillac deal to 2029
-
منصور بن زايد: يوم زايد المؤسس يجدد الاعتزاز بإرث الوالد المؤسس
-
Investors turn cautious ahead of tech results, Fed update on rates
-
محمد بن راشد: يوم زايد المؤسس احتفاء بالوحدة وباني نهضة الإمارات
-
Arab Israelis proud of high election turnout, uncertain for future
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
Inglis, Carey put Australia in command of South Africa decider
-
غرف دبي ودي إتش إل تتعاونان لدعم توسع الشركات في الأسواق العالمية
-
Bolsonaro flees Brazil for US after election defeat
-
French firm Safran helps build aircraft wings of the future in UK factory
-
وكيل ذكاء اصطناعي يرصد أربع ثغرات في برمجيات منشآت الاندماج النووي
-
A throne on wheels, popemobiles star in new Vatican show
-
Ceasefire in Russia-occupied Ukrainian city holds for second day
-
Spain high-speed train crash kills 68, injures over 100
-
Canada hikes rates to contain oil price surge caused by Iran war
-
UK woman drugged by husband tells rape trial she woke up bound
-
خالد بن محمد ومارك كارني يبحثان توسيع الشراكة الإماراتية الكندية
-
World Bank warns of worsening food insecurity as commodity prices soar
-
Clean-up starts as Serbian students movement prepares to govern
-
كيف تستخدم البنوك المركزية أدواتها عند تراجع العملات؟
-
Mona Lisa scrubbed from Syrian textbooks as critics slam conservative drift
-
الدولار يستقر فوق 56 جنيهاً في البنوك المصرية الأربعاء
-
Flavio Bolsonaro: right-wing heir falls from presidential hopeful to exile
-
Bolsonaro flees Brazil for US after election defeat: AFP
-
UK budget lifts bank tax to offset surging energy bills
-
Brazil's Bolsonaros: between power, prison, and exile
-
النفط يصعد أكثر من 1% والأسواق تترقب بيانات المخزونات الأميركية
-
Spain high-speed train collision kills 64, injures over 100
-
مبادرة مصرية جديدة لمساندة صغار مزارعي القمح ورفع الإنتاجية
-
Israel president urges against new vote despite inconclusive result
-
Brazil's Bolsonaro lands in Florida after election defeat: AFP
-
أوبن إيه آي تتجه لشراء رقائق جوجل لزيادة طاقتها الحاسوبية
-
Eala recovers to move into Tokyo quarter-finals
-
Russia woos African leaders at Moscow summit
-
COPs 'bunch of baloney' says Panama as it vies to host nature summit
-
Local ceasefire in Russia-occupied Ukrainian city holds for second day
-
طفرة رقائق الذاكرة ترفع إيرادات إس كيه هاينكس بأكثر من 300%
-
Denmark mulls banning turbo chickens
Novo Nordisk vows legal action to protect Wegovy pill
Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
The Danish company only began selling Wegovy in pill form last month after having received approval from the US Food and Drug Administration, but the telehealth company Hims & Hers has begun advertising cheaper versions.
"This is another example of Hims & Hers' historic behaviour of duping the American public with knock-off GLP-1 products," said Novo Nordisk in a statement, referring to the hormone in Wegovy that regulates blood glucose levels and appetite.
"Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework," it added.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Shares in Novo Nordisk have taken a beating this week after it warned of lower sales revenue in the United States as intensified competition pushes down prices.
Y.Zaher--SF-PST